Bacterial Enzyme Improved Mitochondrial Metabolism in Worm and Mouse Studies

A bacterial enzyme delivered through gene therapy improved mitochondrial metabolism and several health-related measures in worm and mouse studies, according to research reported in Science Advances and summarized by Fight Aging!. The findings are preclinical and do not establish that the approach would work in humans.

The enzyme, lipoic acid protein ligase A, or LplA, attaches lipoic acid to proteins in a process known as lipoylation. This modification influences the activity of enzymes involved in metabolism. In mammals, lipoylation is coordinated by multiple enzymes, while the corresponding process in Escherichia coli can be completed by the single LplA enzyme.

The researchers introduced the bacterial enzyme into Caenorhabditis elegans and mouse models and assessed physiological effects across different life stages. The reported results indicated that LplA increased lipoylation and enhanced energy metabolism. The intervention was also associated with lower levels of reactive oxygen species, molecules produced during energy generation that can act as cellular signals at physiological levels but contribute to cellular damage when they accumulate excessively.

In the models studied, the metabolic changes were accompanied by broader physiological effects. Early-life intervention was linked to improved motility and greater stress resistance. When the intervention began later in life, the researchers reported delayed age-related decline and extended health span in the experimental organisms. The source material does not report that the treatment extended lifespan, nor does it show that the findings translate to human aging or human mitochondrial disease.

The work builds on research suggesting that LplA can restore deficient lipoylation, but the reported experiments examined whether the enzyme might also enhance metabolism in otherwise healthy organisms during aging. That makes the study relevant to efforts focused on mitochondrial function and age-related physiological decline, while keeping the evidence firmly at the animal and invertebrate research stage.

Fight Aging! noted a major obstacle to any possible human application: introducing a bacterial protein into people could provoke an adverse immune response. The source describes this as a significant concern and says that demonstrating the absence of such a reaction would present a high bar for development and regulatory approval. No human testing, regulatory authorization, or clinical benefit is reported.